Next-generation HBV Therapeutics: Emerging Therapies and Search for Functional Cure
Nov
09
2025
Convention Center: Room 207, Level 2
5:00 PM
- 6:30 PM
World Class Speakers
Description
This session will feature translational and early-phase clinical studies that are advancing the therapeutic landscape for chronic hepatitis B. Highlights include a novel capsid assembly modulator, early stage HBV immune modulation trial, therapeutic vaccines, antisense oligonucleotides in combination with pegylated interferon, and a preclinical study of an epigenetic editing agent demonstrating HBV surface antigen loss through targeted DNA methylation. Together, these studies showcase innovative pathways toward viral suppression and functional cure.Journey Maps
Presentations
5:15 PM
- 5:30 PM
Apr
29
2026
Washington, D.C.
HBsAg declines observed with VRON-0200 alone are rapidly enhanced with the addition of combination antiviral therapies: results from a Phase 1b study for functional cure in chronically HBV-infected patients
Grace Lai-Hung Wong, MD, MBChB (Hons), FRCP, FHKCP, FHKAM
, Abstract Presenter
Hepatitis
5:30 PM
- 5:45 PM
Apr
29
2026
Washington, D.C.
Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis
Edward J Gane, MD, FAASLD
, Abstract Presenter
Hepatitis
Objectives
- Describe emerging therapeutic strategies for chronic HBV, including mechanisms targeting capsid assembly, immune restoration, and epigenetic regulation
- Evaluate novel approaches to HBV including antisense oligonucleotides, monoclonal antibodies, and therapeutic vaccines
- Interpret preclinical and early-phase trial data to understand their potential impact on future viral hepatitis treatment paradigms